8-ethylquinazoline-4(3H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 8-ethylquinazoline-4(3H)-one
• 英文别名: 8-ethylquinazolin-4(3H)-one；8-Ethyl-3,4-dihydroquinazolin-4-one；8-ethyl-3H-quinazolin-4-one
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: QUWMISWQMPOAEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160083368A1

  公开（公告）日：2016-03-24

  Compounds of formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明揭示了化学式I的化合物或其盐。本发明还揭示了包括化合物I的药物组合物，制备化合物I的方法，用于制备化合物I的中间体以及治疗Retroviridae病毒感染，包括HIV病毒感染的治疗方法。
• Cot modulators and methods of use thereof
  申请人：Gilead Sciences, Inc.

  公开号：US10947259B2

  公开（公告）日：2021-03-16

  The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

  本公开一般涉及Cot（癌症大阪甲状腺）的调节剂及其使用和制造方法。
• HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS
  申请人：AstraZeneca AB

  公开号：US20200109153A1

  公开（公告）日：2020-04-09

  The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：GILEAD SCIENCES INC

  公开号：WO2014134566A2

  公开（公告）日：2014-09-04

  Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.